We expect investors to focus on Altimmune’s ALT progress in the studies evaluating its lead pipeline candidate, pemvidutide, ...

Altimmune's pemvidutide showed strong MASH resolution and good tolerability in IMPACT, but fibrosis data fell short. See why ...

About Altimmune Inc. Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel ...

Altimmune Inc. (NASDAQ: ALT) is completing a Phase 2 clinical trial of pemvidutide, an anti-obesity drug that appears to be able to bring important benefits to weight loss.

Altimmune ALT is developing its lead candidate, pemvidutide, a novel, investigational and peptide-based GLP-1/glucagon dual receptor agonist for treating obesity and metabolic dysfunction ...

Altimmune Inc. ALT shares rallied more than 40% in the extended session Thursday after the clinical-stage biopharma company said 391 people enrolled in a trial of its obesity drug pemvidutide lost ...

Altimmune, a clinical-stage biopharmaceutical company, is making strides in its peptide research, developing therapeutic agents with the potential to treat serious health conditions like liver ...

Altimmune is one of several smaller biotech companies that are pushing to compete directly with Novo Nordisk and Eli Lilly in the growing weight loss drug space, or to get scooped up by larger ...

--Altimmune, Inc., a late clinical-stage biopharmaceutical company, today announced that members of the Company’ s management team will participate in a fireside chat at the Citizens Life ...

But in Altimmune's late-stage trial, more than 74% of the weight that patients lost after taking the company's weekly injection came from fat tissue and only 25.5% came from lean mass, according ...